Eric Fischer, Ph.D. is an Independent Investigator and the Director of the Chemical Biology Program at Dana-Farber Cancer Institute, Associate Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, and Co-Director of the DFCI Center for Protein Degradation. Dr. Fischer trained in structural biology and biochemistry at the University of Basel and conducted his doctorate studies at the Friedrich Miescher Institute for Biomedical Research. During his graduate work, he has been recognized for pioneering work on the mechanism of action of thalidomide. Since moving to Boston, his lab focuses on the understanding of fundamental processes in ubiquitin signaling, and the molecular basis of ubiquitin ligase activity, targeting and regulation. His lab seeks to leverage this understanding for the development of novel therapeutic approaches, such as targeted protein degradation. He and his lab have significantly contributed to our understanding of small molecule mediated protein degradation, and its widespread application in academia and industry. Dr. Fischer has co-founded Civetta Therapeutics, Proximity Therapeutics and Neomorph and serves on the scientific advisory board for the Institute for Protein Innovation, Avilar Therapeutics and Photys Therapeutics.